GSK plc announced plans to invest $30 billion in the United States over the next five years, focusing on research and development and supply chain infrastructure. This major investment aims to strengthen GSK’s innovation and manufacturing presence in the U.S., producing medicines locally for American patients.
A key part of this commitment is a $1.2 billion investment in advanced manufacturing facilities and cutting-edge digital technologies, including artificial intelligence (AI). This funding will support the creation of next-generation biopharma factories and laboratories. Construction will begin in 2026 on a new biologics flex factory in Upper Merion, Pennsylvania, designed to develop new medicines for respiratory diseases such as COPD and asthma, as well as various cancers.
In addition, GSK plans to enhance AI and digital capabilities across its five existing U.S. manufacturing sites located in Pennsylvania, North Carolina, Maryland, and Montana. The company will also expand drug substance manufacturing and improve device and auto-injector production and assembly.
GSK CEO Emma Walmsley emphasized the significance of the investment amid the recent U.K.-U.S. State Visit, highlighting the shared commitment to advancing life sciences. “We are proud to be part of both countries’ innovation ecosystems,” Walmsley said. “This $30 billion investment will further bolster our U.S. R&D and supply chain operations and create hundreds of skilled jobs.”
The U.S. will become GSK’s leading country for clinical trials over the next five years, with increased investment in drug discovery, development, and trial activities. Recent construction projects include an $800 million expansion of the Marietta, Pennsylvania site, doubling its capacity.
GSK currently employs approximately 15,000 people in the U.S., and the new investments will support job growth in manufacturing and related sectors. Globally, GSK’s supply chain delivered 1.7 billion packs of medicines and over 400 million vaccine doses last year, contributing to its goal of positively impacting 2.5 billion people by 2030.